151 related articles for article (PubMed ID: 2567957)
1. [Nizatidine].
Romero M; Franzosi MG
Medicina (Firenze); 1989; 9(1):93-6. PubMed ID: 2567957
[TBL] [Abstract][Full Text] [Related]
2. A comparison of nizatidine with the three other histamine receptor antagonists for duodenal ulcer therapy.
Lima M; Holdcroft C
Nurse Pract; 1989 Feb; 14(2):41-2. PubMed ID: 2564655
[TBL] [Abstract][Full Text] [Related]
3. Clinical review of histamine2 receptor antagonists.
Lipsy RJ; Fennerty B; Fagan TC
Arch Intern Med; 1990 Apr; 150(4):745-51. PubMed ID: 1970232
[TBL] [Abstract][Full Text] [Related]
4. Nizatidine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease.
Price AH; Brogden RN
Drugs; 1988 Nov; 36(5):521-39. PubMed ID: 2905640
[TBL] [Abstract][Full Text] [Related]
5. Nizatidine and ranitidine in the short-term treatment of duodenal ulcer: a cooperative double-blind study of once-daily bedtime administration.
Pace F; Colombo E; Ferrara A; Prada A; Rocca F; Bianchi Porro G
Am J Gastroenterol; 1988 Jun; 83(6):643-5. PubMed ID: 2897784
[TBL] [Abstract][Full Text] [Related]
6. The effect of an oral morning dose of nizatidine and ranitidine on gastric acid secretion in duodenal ulcer patients.
Lazzaroni M; Bianchi Porro G
Hepatogastroenterology; 1989 Dec; 36(6):490-3. PubMed ID: 2575571
[TBL] [Abstract][Full Text] [Related]
7. Nizatidine versus ranitidine in the treatment of peptic ulcer disease: report on the Dutch investigation as part of a European multicentre trial.
Kuipers EJ; Hazenberg HJ; Quik RF; Hazenberg BP; de Zwart PA
Neth J Med; 1990 Aug; 37(1-2):58-62. PubMed ID: 1977089
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of acute stomach ulcer with H2 receptor antagonists. A direct therapy comparison with 300 mg nizatidine nightly and 2 times 150 mg nizatidine with twice daily 150 mg ranitidine].
Arnold R; Beckenbach P; Bock H; Bormann R; Brunner G; Daake H; Dammann HG; Dietrich K; Fuerer M; Geiter B
Fortschr Med; 1989 Jun; 107(17):390-4. PubMed ID: 2568327
[TBL] [Abstract][Full Text] [Related]
9. Famotidine. The ACG Committee on FDA-Related Matters with primary authorship by G. Friedman. American College of Gastroenterology.
Am J Gastroenterol; 1987 Jun; 82(6):504-6. PubMed ID: 2883885
[TBL] [Abstract][Full Text] [Related]
10. Nizatidine: a new histamine receptor blocker in the treatment of active duodenal ulcers.
Levendoglu H; Mehta B; Wait C; Reddy G; Hatcher C
Am J Gastroenterol; 1986 Dec; 81(12):1167-70. PubMed ID: 2878607
[TBL] [Abstract][Full Text] [Related]
11. Nizatidine in the short-term treatment of duodenal ulcer--an Italian Multicenter Study.
Bovero E; Poletti M; Boero A; Mura BC; Camarri E; Corradini P; Corsini G; Federici G; Curzio M; Gianquinto G
Hepatogastroenterology; 1987 Dec; 34(6):269-71. PubMed ID: 2892768
[TBL] [Abstract][Full Text] [Related]
12. Histamine H2-receptor antagonists.
Pounder R
Baillieres Clin Gastroenterol; 1988 Jul; 2(3):593-608. PubMed ID: 2901868
[TBL] [Abstract][Full Text] [Related]
13. Famotidine in the USA: a review of efficacy studies.
Gitnick G
J Int Med Res; 1989; 17 Suppl 1():17A-24A. PubMed ID: 2566539
[TBL] [Abstract][Full Text] [Related]
14. Comparison of 150 mg nizatidine BID or 300 mg at bedtime, and 150 mg ranitidine BID in the treatment of gastric ulcer--an 8-week randomized, double-blind multicentre study.
Di Mario F; Battaglia G; Naccarato R; D'Angelo A; Saggioro A; Da Broi GL; Vezzadini P; Bianchi Porro G
Hepatogastroenterology; 1990 Dec; 37 Suppl 2():62-5. PubMed ID: 1982108
[TBL] [Abstract][Full Text] [Related]
15. [The effects of nizatidine and misoprostol on peptic activity and gastric mucus].
Grassi SA; Vianello F; Germanà B; Dal Santo P; Faggian D; Battaglia G; Plebani M; Di Mario F; Naccarato R
Medicina (Firenze); 1990; 10(1):29-31. PubMed ID: 1974318
[TBL] [Abstract][Full Text] [Related]
16. [Effects of nizatidine, a new histamine H2-receptor antagonist, on gastric acid secretion and various gastric and duodenal lesions in rats: comparison with cimetidine].
Okabe S; Takeuchi K; Okada M; Kumadaki Y; Nakata M; Nakata H
Nihon Yakurigaku Zasshi; 1989 Mar; 93(3):133-44. PubMed ID: 2567267
[TBL] [Abstract][Full Text] [Related]
17. Lack of gastric acid rebound after stopping a successful short-term course of nizatidine in duodenal ulcer patients.
Savarino V; Mela GS; Zentilin P; Sumberaz A; Bonifacino G; Celle G
Am J Gastroenterol; 1991 Mar; 86(3):281-4. PubMed ID: 1671805
[TBL] [Abstract][Full Text] [Related]
18. Nocturnal acid suppression with a new H2 receptor antagonist--nizatidine.
Dammann HG; Gottlieb WR; Walter TA; Dreyer M; Müller P; Simon B; Keohane P
Hepatogastroenterology; 1986 Oct; 33(5):217-20. PubMed ID: 2879782
[TBL] [Abstract][Full Text] [Related]
19. [Nizatidine versus ranitidine in the treatment of acute duodenal ulcer. Comparison of 300 mg nizatidine and 300 mg ranitidine in a single evening dose].
Arnold R; Beckenbach P; Bock H; Bormann R; Daake H; Dammann HG; Du Bosque G; Fürer M; Geiter B; Hebbeln H
Fortschr Med; 1989 Jul; 107(21):467-70. PubMed ID: 2570012
[TBL] [Abstract][Full Text] [Related]
20. Fourth histamine antagonist, nizatidine, reaches U.S. market.
Clin Pharm; 1988 Aug; 7(8):560. PubMed ID: 2901936
[No Abstract] [Full Text] [Related]
[Next] [New Search]
